Acadia Pharmaceuticals (NASDAQ:ACAD) reported 3/31/2018 earnings this Afternoon, coming in at ($0.44) per share, beating Wall Street’s estimates of ($0.56) per Share. Revenue for the quarter came in at $48.90 million beating analyst estimates of $47.06 million Recent Insider Trading for Acadia Pharmaceuticals (NASDAQ:ACAD)
- On 3/1/2018 Daniel B Soland, Director, bought 7,000 with an average share price of $23.91 per share and the total transaction amounting to $167,370.00.
- On 1/29/2018 Glenn Baity, EVP, sold 36,558 with an average share price of $32.39 per share and the total transaction amounting to $1,184,113.62.
- On 1/2/2018 Glenn Baity, EVP, sold 74,321 with an average share price of $30.14 per share and the total transaction amounting to $2,240,034.94.
- On 1/2/2018 Laura Brege, Director, sold 25,000 with an average share price of $30.06 per share and the total transaction amounting to $751,500.00.
- On 10/5/2017 Glenn Baity, EVP, sold 37,500 with an average share price of $40.91 per share and the total transaction amounting to $1,534,125.00.
- On 8/30/2017 Glenn Baity, EVP, sold 26,507 with an average share price of $34.87 per share and the total transaction amounting to $924,299.09.
Dividend History for Acadia Pharmaceuticals (NASDAQ:ACAD)
Recent Trading for Acadia Pharmaceuticals (NASDAQ:ACAD) Shares of Acadia Pharmaceuticals closed the previous trading session at 16.04 +0.00 0.00% with 17.190000534057617 shares trading hands.